FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine. A method for functional and quantitative evaluation of platelet-monocyte complexes (PMCs) in whole peripheral blood samples is proposed. For this purpose, the blood is stabilized within no more than 1 minute after sampling from the ulnar vein, a flow cytometry test is performed using a panel of diagnostic markers CD45/CD14/CD41a/CD16/CD62P/CD40/CD11b/CD162/CD142. CD40 is used to identify PMC with the function of proinflammatory activity, CD11b marker is used to identify PMCs with the function of adhesive activity, CD62P/CD162/CD142 markers are used to identify PMCs with the function of prothrombotic activity, CD45/CD14/CD41a/CD16 markers are used to identify formed PMCs from the total pool of peripheral blood cell elements with determination of their number.
EFFECT: invention makes it possible to assess the activation status of PMCs both in the general population of monocytes and in their individual subpopulations.
1 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
| METHOD AND MEANS FOR MONITORING OF TISSUE HOMEOSTASIS IN ORGANISM | 2012 |
|
RU2635767C2 |
| DIAGNOSTIC TECHNIQUE FOR SPONTANEOUS SECONDARY IMMUNE DEFICIENCY IN CHILDREN WITH PRIMARY PERITONITIS | 2013 |
|
RU2527332C1 |
| METHOD OF DIFFERENTIAL EXPRESS DIAGNOSTICS OF ACUTE VIRAL AND BACTERIAL INFECTIONS | 2015 |
|
RU2602677C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF BACTERIAL AND VIRAL INFECTIOUS-INFLAMMATORY DISEASES | 2024 |
|
RU2825251C2 |
| HUMANISED MOUSE M-CSF | 2012 |
|
RU2577978C2 |
| CELLULAR SYSTEM FOR TARGETED DELIVERY OF A PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL | 2016 |
|
RU2771323C2 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| HUMANIZED M-CSF MICE | 2020 |
|
RU2819731C2 |
| DENDRITIC CELL GENERATION FROM MONOCYTIC DENDRITIC CELL PRE-CURSORS BY MEANS OF GM-CSF IN ABSENCE OF ADDITIONAL CYTOKINES | 2004 |
|
RU2364625C2 |
